share_log

TC BioPharm | 8-K: Current report

SEC announcement ·  Feb 15 04:08
Summary by Futu AI
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
On February 13, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, issued a shareholder update via press release, detailing significant operational achievements and outlining future milestones. The company, listed on NASDAQ under the symbol TCBP, announced FDA clearance for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML) and a collaboration with Queen Mary University of London to expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases. TC BioPharm also reported an approximate $11.6 million in cost-savings and the successful completion of the ACHIEVE Study safety cohort. Additionally, the company filed a preliminary proxy statement with the SEC on February 9, 2024, seeking shareholder approval for a potential issuance of shares that could exceed 20% of the outstanding shares at a discounted price, in accordance with Nasdaq Marketplace Rule 5635(d). The Board of Directors has not yet determined the terms of any potential financing. The company emphasized its focus on strategic partnerships and budget savings for the year ahead.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.